Navigation Links
Advanced Therapy Aids Stroke Patients
Date:1/23/2008

Procedure brings clot-busting drugs right to site of blood clot, study reports

WEDESDAY, Jan. 23 (HealthDay News) -- Therapies that attack blood clots directly in the brain may benefit ischemic stroke patients who don't respond to the standard treatment using clot-busting drugs.

So says a U.S. study that was to have been presented Tuesday at the 20th annual International Symposium on Endovascular Therapy, in Hollywood, Fla.

Ischemic strokes -- which account for about 83 percent of strokes -- occur when a small clot blocks an artery in the brain and halts blood flow, according to the American Stroke Association. If the clot isn't cleared and blood flow restored, the patient will suffer permanent brain damage or death.

"Often patients who fail to improve with standard intravenous (IV) stroke therapy aren't given the chance to succeed with more advanced intra-arterial (IA) therapy, because it's thought that it won't work if IV therapy didn't, and that it will increase the risk of bleeding in the brain," study author Dr. Christopher Zylak, director of neurointerventional radiology at Sacred Heart Medical Center in Spokane, Wash., said in a prepared statement. "Our data suggest that IA therapy can be highly successful even when IV therapy doesn't work, and that the risk of bleeding is no different between the two therapies."

In IV therapy, clot-busting drugs are delivered through an intravenous device in the patient's arm. IV treatment must begin within three hours of the onset of stroke, which means patients must get to the hospital at the first signs of stroke.

IA therapy involves placing a catheter through a small incision in the patient's groin and moving the catheter through an artery all the way to the site of the blockage in the patient's brain. This enables direct delivery of clot-busting drugs to the area. Doctors also can use the catheter to insert a tiny corkscrew-like device to remove the
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Foundation Radiology Group Formalizes Strategic Partnership with Emageon to Provide Advanced Imaging Software to Facilitate Industry-Leading Turnaround and Patient Care Response Times
2. Advanced Home Care Extends Its Use of Authentidates Inscrybe(TM) Healthcare Platform
3. Bevacizumab found to improve survival for patients with advanced breast cancer
4. Study examines factors associated with survival in advanced laryngeal cancer
5. With Calorie Counting on Holiday Hiatus, NutriSystem Offers Advanced Resolution for 2008
6. New Survey Underscores Importance of Psychosocial and Educational Needs Among Women with Advanced Breast Cancer
7. Survey underscores importance of emotional/educational needs among women with advanced breast cancer
8. Advanced Life Sciences Completes Private Placement for $20 Million
9. Neupro(R) Filed with the FDA for the Treatment of Advanced-Stage Parkinsons Disease
10. Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma
11. Advanced Clinical Research Services Enhances Biostatistics Offering
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Advanced Therapy Aids Stroke Patients
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 (HealthDay ... (IVF) -- the incubation of embryos in a laboratory dish ... vagina, new research suggests. Scientists from the United States ... sharply cut costs for pricey IVF procedures among certain women. ... who don,t live near big-city assisted reproduction centers, the researchers ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... officials on Monday officially tightened guidelines for health workers treating ... exposure and use of a respirator at all times. ... issue the tougher rules after two Dallas nurses contracted Ebola ... United States, Liberian national Thomas Eric Duncan. Nina Pham is ...
(Date:10/20/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... is the must-have source of thousands of facts, figures ... 72 countries and 68 medical sector forecast categories the ... you with global, regional and national views on the ... future outlook. , The report gives you data for ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Allegheny General ... procedure that enables physicians to repair a damaged mitral ... MitraClip system, developed by Abbott Vascular ... a progressive and life-threatening condition in which the heart’s ... to flow backward from the heart’s left ventricle into ...
(Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... that hepatitis C virus infection is a bad ... in renal transplant recipients//. ,Hepatitis C virus (HCV) ... recipients; the prevalence depends on the geographic area. ... renal transplant recipients. ,Researchers from the Armed ...
... Health Minister Anbumani Ramadoss has said that the government is ... and plans to take several steps to check female foeticide, ... ,Dr Ramadoss said that there were plans to set up ... unfortunate practice that prevails on a large scale in the ...
... is to be started by British Heart Foundation to encourage children’s ... the food which will help them to educate about healthier foods//. ... content of the foods they eat. ,More than 10% ... and 37% of children’s were not aware that cheese was made ...
... Institute of Medical Research (QIMR) have found that regular ... which are precursors to skin cancer//. The study was ... Dermatology. ,Aspirin is a cyto-oxygenase (COX) enzyme ... its expression. The COX gene is gene coded which ...
... Clinical Global Health Education was started by Bob Bollinger ... care to patients would improve only if health care ... was to provide training by John Hopkins through Global ... providers. Bollinger said, “Don’t wait for poorly funded medical ...
... Recent research demonstrates that erythrocyte sedimentation rate (ESR) ... haemoglobin concentration significantly influence ESR//. ,The erythrocyte ... the acute phase response. It is helpful in ... to treatment. It is influenced by anaemia, which ...
Cached Medicine News:Health News:John Hopkins CGHH program provides Global Health education 2
(Date:10/22/2014)...   Surefire Medical , Inc., the developer of ... targeted delivery of embolization agents in minimally invasive direct-to-tumor ... John R. Daniels , MD of the University of ... Steven C. Katz , MD of the Roger ... Board (SAB).    "The role of the ...
(Date:10/22/2014)... and AUSTIN, Texas ... and PureMHC LLC today announced they have entered ... novel antibody-based immunotherapies designed to target cancers. ... phosphorylated peptides displayed on the surfaces of tumor ... tumor targets (PTTs), derived from proteins that play ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) has ... significantly oversubscribed. The issue price under the Placement ... price of QRxPharma shares on 28 September 2010 of A$1.00. ... oversubscriptions from investors and increase the size of the placement from ...
... Radio (Nasdaq: SIRI ) today announced that Andrew ... Center, will host the next edition of his Doctor Radio ... on the link between early antibiotic use in children and ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080819/NYTU044LOGO ) Dr. Brotman,s guests will ...
Cached Medicine Technology:QRxPharma Limited Announces A$14 Million Placement Together With a Share Purchase Plan 2QRxPharma Limited Announces A$14 Million Placement Together With a Share Purchase Plan 3SIRIUS XM's Doctor Radio's 'The Dean's List' To Focus On Link Between Early Antibiotic Use In Children And Obesity 2SIRIUS XM's Doctor Radio's 'The Dean's List' To Focus On Link Between Early Antibiotic Use In Children And Obesity 3SIRIUS XM's Doctor Radio's 'The Dean's List' To Focus On Link Between Early Antibiotic Use In Children And Obesity 4
... Our ELISA products for autoimmune testing feature ... as well as specific reflex tests including ... Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and ... includes a full line of products for ...
... autoimmune testing feature single-well ANA screen and ... reflex tests including dsDNA, and 6 individual ... (La), Scl-70 and Jo-1. In addition, our ... of products for Cardiolipins (IgA, IgG, IgM), ...
... ELISA products for autoimmune testing feature single-well ... well as specific reflex tests including dsDNA, ... SS-A (Ro), SS-B (La), Scl-70 and Jo-1. ... a full line of products for Cardiolipins ...
... Our ELISA products for autoimmune testing ... ELISAs, as well as specific reflex tests ... Sm, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 ... family includes a full line of products ...
Medicine Products: